在脊髓肌肉缩中,SMN 缺乏会扰乱单胺神经递质代谢
Valeria Valsecchi1, Francesco Errico2,3, Valentina Bassareo4
1Division of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, School of Medicine, University of Naples "Federico II", 80131, Naples, Italy.
Communications biology
|November 13, 2023
概括
脊髓肌肉缩 (SMA) 不仅涉及运动神经元,还会导致代谢问题. 低存活率运动神经元 (SMN) 蛋白质影响大脑和肝脏的能量和氨基酸代谢,影响像诺阿基因林这样的神经递质.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
背景情况:
- 脊髓肌肉缩 (SMA) 主要以运动神经元退化而闻名.
- 幸存运动神经元1 (SMN1) 基因中的同卵性突变导致SMA.
- 多系统和代谢缺陷发生在SMA中,但其生物化学细节和发病不清楚.
研究的目的:
- 调查SMA中精确的生化特征和代谢变化的开始.
- 探索SMN缺乏对大脑和肝脏新陈代谢的影响.
- 检查SMN水平和SMA中单胺代谢之间的关系.
主要方法:
- 在SMA小鼠模型中,基于NMR的非向代谢.
- 高性能液态染色学 (HPLC) 分析.
- 对关键代谢基因的mRNA和蛋白质表达的分析.
主要成果:
- 在SMA小鼠中发现了能量稳定和氨基酸代谢中的大脑和肝脏异常,在出生后的第三天就有明显的肝脏变化.
- 在患有症状的SMA小鼠中,SMN缺乏导致出生后第11天脑中上腺素水平降低.
- SMN 缺乏影响了调节单胺代谢 (AADC,DβH,MAO-A) 的基因表达.
- 在SMA患者中,努辛森治疗增加了脑脊髓液的诺尔上腺素,支持了临床前发现.
结论:
- 低SMN水平会对单胺代谢中的关键酶产生负面影响.
- 诱导SMN的疗法可能提供一种调节catecholamine神经传递的策略.
- 这些发现与解决 SMA 中的外周代谢缺陷有关.
- 这项研究揭示了SMN缺乏和SMA代谢失调之间的新联系.
更多相关视频
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Chemical Synapses
8.9K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.9K
Myasthenia Gravis: Diagnostic Tests
914
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
914
Skeletal Muscle Relaxants: Adverse Effects
376
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
376
Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Disorders of the Skeletal Muscle
966
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
966


